STATEMENT: Cambrex opens a new stability warehouse in Belgium


STATEMENT: Cambrex opens a new stability warehouse in Belgium

EAST RUTHERFORD, N.J., April 4, 2023 /PRNewswire/ -- Cambrex, one of the world's leading contract development and manufacturing organizations (CDMOs) providing pharmaceutical product, substance and analytical services throughout the entire manufacturing life of drugs, today announced that its stability storage division, Q1 Scientific, has opened a new 20,000 square foot cGMP facility in Belgium, expanding its ability to provide environmentally controlled stability storage services to industries pharmaceutical, medical device and life sciences across Europe.

Strategically located in the Liège region and around 90 kilometers from Brussels, the new state-of-the-art temperature-controlled and monitored storage facility offers 35,000 temperature-controlled storage spaces for all key ICH climate zones, including long-term stability tests. term, intermediate and accelerated, including 2 - 8°C, 25°C / 60%RH and 40°C / 75%RH.

Tom Loewald, Cambrex CEO, said: "Following our acquisition of Q1 Scientific in June 2022, we have continued to see increased demand for stability storage services. This expansion provides readily accessible capacity in continental Europe as well as such as flexibility to react quickly and effectively to changing customer requirements."

From this new location, Q1 Scientific will serve pharmaceutical companies across Europe under the leadership of the new CEO of Belgium, Cécile Jacoby.

Stephen Delaney, Managing Director of Q1 Scientific said: "The opening in Belgium is a significant milestone for Q1 Scientific and we are delighted to expand our rapidly growing stability storage business. Having two sites will be very beneficial for our European customers, that they can now count on more options for temperature-controlled transport in continental Europe."

This expansion in Belgium complements Q1 Scientific's existing presence in Waterford, Ireland, and is consistent with Cambrex's strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing in North America and Europe.

About Cambrex

Cambrex is a world-leading contract development and manufacturing organization (CDMO) providing pharmaceutical, substance and analytical services throughout the entire drug lifecycle. With over 40 years of experience and a growing team of more than 2,400 experts serving global customers in North America and Europe, Cambrex is a trusted partner in the brand and generic markets for the development and manufacturing of APIs and dosage forms. finished.

Cambrex offers a range of specialized pharmaceutical substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, materials characterization, and high-powered APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialized dosage forms such as modified-release, fixed-dose combination, pediatric, bilayer tablets, stick packs, topicals, substances controlled, sterile and non-sterile ointments.

About Q1 Scientific

Q1 Scientific, a Cambrex company, provides environmentally controlled stability storage services to the pharmaceutical, medical device and life sciences industries in its 20,000 square foot cGMP facility. As the first company in the industry to establish itself in Ireland, Q1 Scientific is revolutionizing the way pharmaceutical companies store their products, helping to improve the speed with which new medicines come to market and saving companies the expense of building and oversee their own storage chambers.

Logo - -

View original content: